Search results
Results from the WOW.Com Content Network
Flibanserin, sold under the brand name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). [ 4 ] [ 5 ] The medication improves sexual desire, increases the number of satisfying sexual events, and decreases the distress associated with low sexual desire. [ 6 ]
Flibanserin, a drug used for female sexual dysfunction, is a 5-HT 1A receptor partial agonist. [ 1 ] Many atypical antipsychotics , such as aripiprazole , asenapine , clozapine , lurasidone , quetiapine , and ziprasidone , are 5-HT 1A receptor partial agonists, and this action is thought to contribute to their beneficial effects on negative ...
Flunarizine is a selective calcium antagonist with moderate other actions including antihistamine, serotonin receptor blocking and dopamine D 2 blocking activity. Compared to other calcium channel blockers such as dihydropyridine derivatives, verapamil and diltiazem, flunarizine has low affinity to voltage-dependent calcium channels.
Bremelanotide does not meaningfully interact with alcohol, unlike flibanserin (for which the interaction with alcohol is a major barrier to its use). [ 13 ] [ 14 ] However, bremelanotide does interact with certain medications that people take by mouth.
Fenclonine (para-chlorophenylalanine; PCPA) An inhibitor of serotonin synthesis that has been used in the treatment of carcinoid syndrome. Feverfew [2] Is a herb traditionally used for migraines (contains parthenolide [3]). Reserpine Depletes serotonin stores in the brain, heart, and many other organs and has been used in hypertension and psychosis
Eltoprazine (developmental code name DU-28,853) is a serotonergic drug of the phenylpiperazine class which is described as a serenic, or anti-aggressive agent. [1] [2] [3]It acts as an agonist of the serotonin 5-HT 1A and 5-HT 1B receptors and as an antagonist of the serotonin 5-HT 2C receptor.
Pimavanserin was studied as a therapeutic agent in Phase III clinical trials for major depressive disorder and schizophrenia and Phase II trials for agitation. It was also under development for the treatment of insomnia, drug-induced akathisia, and drug-induced dyskinesia, but development for these indications was discontinued. [4]
Mianserin, sold under the brand name Tolvon among others, is an atypical antidepressant that is used primarily in the treatment of depression in Europe and elsewhere in the world. [6]